WebMar 3, 2024 · Description: This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer to determine the efficacy of margetuximab combined with INCMGA00012 (also known as MGA012) (Cohort A) and margetuximab combined with INCMGA00012 or … WebNov 28, 2024 · A phase II trial is currently recruiting patients with Merkel cell carcinoma to participate in a single-arm study evaluating the safety and efficacy of INCMGA00012. 1 The open-label, multicenter study seeks to enroll 90 patients, including at least 52 patients who are treatment-naïve. In addition, only 40 patients who are chemotherapy-refractory will be …
INCMGA00012 (PD-1 antibody) for Pancreatic Cancer
WebSep 22, 2024 · Colorectal Cancer Ovarian Cancer Non Small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck Bladder Cancer Triple Negative Breast Cancer Pancreatic Ductal Adenocarcinoma Castration Resistant Prostate Cancer Gastric/ Gastroesophageal Junction Squamous Carcinoma of the Anal Canal Intervention / Treatment Drug: … WebThe purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC). Participation eligibility … fur vanity room
Clinical trials detail : MGeND
WebSide Effects Management; Pharmacy; Clinical Trials. Breast Cancer Clinical Trials; Lung Cancer Clinical Trials; View All Clinical Trials; Blood Disorders. ... A Phase 1-2 Study Of Combination Therapy With INCMGA00012 (Anti PD-1), INCAGN02385 (Anti LAG-3), And INCAGN02390 (Anti TIM-3) In Participants With Select Advanced Malignancies. Learn more. WebThe purpose of the study is to determine the safety and efficacy of INCMGA00012 monotherapy or in combination with other immunotherapy or targeted agents (combinations of INCMGA00012 with epacadostat and pemigatinib) for participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based … givenchy net worth